Article, News
Prescient (ASX: PTX) signs off FY22 with solid progress in clinical pipeline
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is working towards expanding its next-generation cell immunotherapy program. At the same time, Prescient is advancing major clinical programs, PTX-100 and…
Article, News
Prescient signs cell manufacturing deal ahead of OmniCAR trials
An Australian company developing personalised therapies for cancer has joined forces with a specialist cell therapy manufacturer to bolster its capabilities in the lead-up to…
Article, News
Prescient Therapeutics (ASX:PTX) locks in OmniCAR cell manufacturing contract for clinical trials
Prescient Therapeutics (PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its OmniCAR cell lines for its upcoming clinical trials.
Article, News
Prescient unveils new platform after 18 months in stealth mode
Australian biotech company Prescient Therapeutics has publicly revealed its high-performing cell therapy enhancement platform named CellPryme-M, developed in collaboration with the Peter MacCallum Cancer Centre.
Article, News
Prescient Therapeutics unveils high performance cell therapy technology CellPryme-M
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has today unveiled the latest technology in its portfolio, a high-performance platform known as CellPryme-M which is designed to enhance…
Article, News
Prescient Therapeutics (ASX:PTX) unveils new cell therapy platform
Prescient Therapeutics (PTX) has unveiled its new cell therapy manufacturing enhancement technology, CellPryme-M. CellPryme-M is a platform technology that produces superior cells during the cell…